# DESCRIPTION

## BACKGROUND OF THE INVENTION

- motivate molecularly targeted contrast agents
- describe phospholipids-based microbubbles
- limitations of current targeted MBs preparations
- advantages of microfluidic-based processing methods
- introduce problem of producing targeted MBs

## SUMMARY OF THE INVENTION

- introduce methods and compositions
- describe phospholipid-ligand bioconjugates
- describe uniform targeted microbubbles
- provide method of producing phospholipid-ligand bioconjugate
- describe cysteine-maleimide conjugation approach
- introduce affibodies modified with C terminal cysteine residues
- describe conjugation of affibody to phospholipid polymer
- describe formation of phospholipid-ligand conjugate micelles
- describe production of targeted microbubbles
- describe binding of targeted microbubbles to cells
- introduce heating and cooling steps
- describe phospholipid polymers and ligands
- describe conditions for contacting phospholipid and ligand

## DETAILED DESCRIPTION OF THE EMBODIMENTS OF THE INVENTION

- define scope of invention
- describe terminology used
- explain range of values
- define mole percent
- describe thiol-Michael addition reaction
- define PEG
- describe tumor, cancer, and neoplasia
- define antibody
- describe single-chain antibody
- define B7-H3
- describe diabody
- define affibody
- describe affibody properties
- explain affibody imaging
- describe therapeutic action of affibody
- define microbubble
- describe microbubble composition
- explain microbubble properties
- describe microbubble imaging
- explain microbubble fragmentation
- describe microbubble dissolution
- define recipient
- describe therapeutically effective amount
- define treating
- define prevent
- describe cancer
- define carcinoma
- describe adenocarcinoma
- define in combination
- describe general methods in molecular and cellular biochemistry
- list standard textbooks
- describe reagents and kits
- define inert gas
- describe antibody fragments
- describe humanized antibody molecules
- describe single-chain Fv molecules
- describe minibodies
- describe linear antibodies
- describe affibody molecules
- describe affibody fusions
- describe affibody conjugates

### Methods of Producing Phospholipid-Ligand Bioconjugates

- introduce phospholipid-ligand bioconjugates
- describe method of producing phospholipid-ligand bioconjugates
- specify contacting phospholipid polymer with ligand
- detail heating phospholipid polymer prior to contacting
- specify temperature ranges for heating phospholipid polymer
- specify time periods for heating phospholipid polymer
- describe reducing phospholipid polymer to room temperature
- specify time periods for reducing phospholipid polymer to room temperature
- list phospholipid polymers for use in method
- list ligands for use in method
- specify proteins of interest for ligand binding
- list tumor-specific antigens for ligand binding
- describe versions of therapeutic antibodies as ligands
- specify cells targeted by ligands
- describe cancer cells of interest
- specify ligands specific to B7-H3
- describe amino acid sequences of ligands
- specify linkers for ligands
- describe peptide linkers
- specify conditions for contacting phospholipid with ligand
- specify phospholipid to ligand ratios
- specify pH for contacting phospholipid with ligand
- describe physical characteristics of phospholipid-ligand bioconjugates

### Methods of Producing Target Microbubbles

- define microbubbles
- describe phospholipid-ligand bioconjugates
- describe phospholipid liposomes
- describe inert gases
- describe production of targeted microbubbles
- describe use of multiple phospholipid-ligand bioconjugates
- describe specific amounts of phospholipid-ligand conjugates and phospholipids
- describe specific size characteristics of targeted microbubbles
- describe use of microfluidic device
- describe use of mechanical agitation device
- describe production of targeted microbubbles conjugated to therapeutic molecules
- describe phospholipid-therapeutic agent bioconjugates
- describe therapeutic agents
- describe chemotherapeutic agents
- describe toxins
- describe radioactive isotopes
- describe kinase inhibitors
- describe immunomodulators
- describe hormone blockers
- describe conjugation of therapeutic agents to phospholipids
- describe specific characteristics of phospholipid-therapeutic agent bioconjugates
- describe specific examples of therapeutic agents
- describe specific examples of phospholipid-therapeutic agent bioconjugates

### Methods of Treating Cancer

- introduce method of treating cancer
- describe contacting cancer cell with targeted microbubble
- specify phospholipid-ligand bioconjugate composition
- list various ligands that specifically bind to cancer cell proteins
- provide examples of cancer cell proteins targeted by ligands
- describe therapeutic agents conjugated to targeted microbubble
- list various therapeutic agents
- specify effective amounts of targeted microbubble for treatment
- describe factors affecting effective amounts
- provide examples of treatment dosages
- describe treatment regimes
- specify intervals between dosages
- describe sustained release formulations
- describe prophylactic applications
- describe therapeutic applications
- list physiologically acceptable carriers
- describe depot forms of polypeptides
- describe combining targeted microbubble with additional therapeutic agents
- list examples of chemotherapeutic agents
- list examples of biological anti-cancer drugs
- describe combining targeted microbubble with immune checkpoint therapy
- list examples of immune checkpoint therapies
- describe combining targeted microbubble with tumor specific monoclonal antibodies
- list examples of tumor specific monoclonal antibodies

### Compositions

- introduce compositions comprising phospholipid-ligand bioconjugates
- describe compositions comprising targeted microbubbles
- describe compositions comprising targeted microbubbles conjugated to therapeutic agents
- specify pharmaceutically acceptable excipients
- list examples of pharmaceutically acceptable excipients
- describe aqueous buffer formulations
- describe isotonic solutions
- describe preservatives and cryoprotectants
- describe routes of administration

## EXPERIMENTAL

### Introduction

- introduce phospholipids-based microbubbles
- motivate molecularly targeted contrast agents
- describe limitations of current MB synthesis methods
- introduce microfluidic-based processing methods
- describe advantages of microfluidic devices
- motivate lipid-shell MB formulations
- describe limitations of surface-functionalization methods
- introduce phospholipid-ligand bioconjugates
- describe site-specific covalent bonding strategies
- motivate engineered small protein ligands
- describe microfluidic device production of MBs
- motivate importance of labeling consistency
- introduce affibody protein selective against B7-H3
- outline optimized workflow for TMB synthesis

### Results

- test molecular weight of binders by MALDI-TOF
- assess binding affinities to human/mouse B7-H3
- evaluate purities of binders by SDS-PAGE
- test binding efficiency of binders to MS1 hB7-H3 cells
- compare binding efficiency of binders to MS1WT cells
- test binding efficiency of binders to MDA-MB-231 human breast cancer cells
- test binding efficiency of binders to 4T1 murine mammary cancer cells
- remove His-Tag from purified proteins
- test His-Tag removal by enterokinase enzyme-mediated cleavage
- analyze SDS-PAGE results of His-Tag removal
- select ABYACI2 as a clinically translatable ligand
- optimize conjugation of ABYs with Mal-phospholipids
- test conjugation efficiency of ABYAC12 with Mal functional group
- analyze SDS-PAGE results of conjugation reaction
- test conjugation of ABY binder with DSPE-PEG-Mal
- analyze SDS-PAGE results of conjugation reaction
- test stability of DSPE-PEG-ABY conjugate
- store conjugate samples in water or as lyophilized powder
- analyze SDS-PAGE results of stored conjugate samples
- test stability of DSPE-PEG-ABY conjugate in buffer with SDS and reactive amines
- analyze SDS-PAGE results of conjugate stability test
- prepare targeted MBB7-H3 with DSPE-PEG-ABY
- use vialmix based amalgamation method for MB production
- use microfluidic device-based bubble generation for MB production
- measure particle size distribution of MBB7-H3
- test ligand display on targeted MBs by flow cytometry
- test ligand display on targeted MBs by fluorescence microscopy
- validate production of targeted MBB7-H3 by traditional mechanical agitation method
- test binding of DSPE-PEG-ABY bioconjugate to MS1B7-H3 cells
- test binding of DSPE-PEG control micelles to MS1B7-H3 cells
- test binding of MBB7-H3 to MS1B7-H3 cells
- test binding of MBB7-H3 to MS1WT cells
- quantify cell-bound MBs by microscopy
- test binding of MBB7-H3 to tumor vascular endothelial cells in vivo
- perform ex vivo analysis of tumor tissues after MBB7-H3 administration
- image tumor tissues by confocal microscopy
- test target binding activity of MBB7-H3 in vivo
- evaluate distribution of MBB7-H3 in normal organs
- discuss advantages of site-specific bioconjugation approach
- discuss advantages of using small engineered proteins
- discuss scalability of phospholipid-protein bioconjugates for clinical applications
- discuss novelty of using microfluidic chips for producing targeted microbubbles
- summarize results and discuss potential for human studies

### Materials and Methods

- list reagents and chemicals
- describe lipid synthesis process
- detail cell culture conditions
- outline protein modification and expression
- describe protein purification process
- detail biotinylation of ABY
- describe His-Tag removal by enzymatic cleavage
- outline phospholipid-ligand bioconjugation
- describe ABY-Alexa Fluor 647 conjugation
- detail DSPE-PEG-Mal conjugation to ABY
- describe bioconjugate purification
- outline bioconjugate stability tests
- describe flow cytometry analysis
- detail ABY binding to MS1WT and MS1B7-H3 cells
- describe ABY-PEG-dye binding to MS1 cells
- outline preparation of targeted microbubbles
- describe microfluidic system operation
- detail liposome preparation
- describe DSPE-PEG-ABY bioconjugate preparation
- outline microbubble formation
- describe microbubble characterization
- detail validation of ABY display on targeted microbubbles
- describe flow cytometry analysis of ABY display
- outline confocal microscopy analysis
- describe in vitro binding assay of MB to B7-H3
- detail cell culture and MB binding
- describe image processing and analysis
- outline MB binding to B7-H3 target in mouse tumor-associated blood vessels
- describe animal experiment approval
- detail lipophilic staining of MBs
- describe intravenous injection of MBs
- outline tissue extraction and processing
- describe immunofluorescence staining
- detail confocal microscopy analysis
- describe statistical analysis
- outline data presentation

